Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study - PubMed
12 hours ago
- #antiarrhythmic therapy
- #varenicline
- #myocardial infarction
- Varenicline, a partial nAChR agonist, was tested in a phase 2 trial for reducing PVCs post-MI.
- The study was randomized, double-blind, and placebo-controlled with 118 participants.
- Varenicline showed a 60.1% greater reduction in PVC burden compared to placebo.
- Responder rate (≥50% PVC reduction) was higher with varenicline (67.8% vs 30.5%).
- Nonsustained VT incidence was lower in the varenicline group (20.3% vs 37.3%).
- No deaths or malignant arrhythmias occurred with varenicline, and adverse events were comparable.
- Results support cardiac nAChRs as a potential antiarrhythmic target.
- Further evaluation in larger trials is justified.